Bret Jensen

Summary AI infrastructure capex, exceeding $700B for FY2026, is the primary engine behind U.S. equity markets and GDP growth.

Here are two cover-call trades I’m working on and why they look promising.

Summary Legend Biotech Corporation remains a decent cell therapy play, with Carvykti showing strong efficacy and underpenetrated multiple myeloma markets.

Summary The current AI-driven market environment closely mirrors the late stages of the 1999 Internet Boom, with extreme valuations and concentration risks.

Summary Market trades near all-time highs with extreme valuations, driven by passive investing and questionable underlying metrics.

A slow and steady approach with these stable biopharma stocks offers refuge from a market that feels ready to pop.

Wall Street has turned negative on this software giant. Here’s why I’m willing to step in.

Summary Equity markets remain near all-time highs despite rising macroeconomic risks, stretched valuations, and heavy concentration in tech and semiconductors.

Small business bankruptcy filings are spiking, more cracks are forming in the housing market … and eventually something’s gotta give.

The U.S. economy and equity markets outside the AI-related areas are under significant pressure from multiple converging risks.